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Abstract: BCR-ABL1 fusion transcript is the minimal residual disease marker in chronic myeloid
leukemia; 2% of patients show unusual breakpoints generating atypical transcripts, not quantifiable
by standardized real-time PCR (RT–PCR). Response monitoring is performed by non-quantitative
NESTED PCR, useless for evaluating patients’ molecular remission, excluding them from
treatment-free-remission protocols. Droplet digital PCR (ddPCR) is highly sensitive technology,
allowing an absolute quantification independent of standard curves. Based on this, we have developed
assays able to evaluate the molecular response in atypical patients. We designed new ddPCR-based
molecular assays able to quantify atypical BCR-ABL1 transcripts, with a detection limit of 0.001%,
validated in a cohort of 65 RNA from 11 patients. Fifty samples were identified congruently by ddPCR
and NESTED PCR (40 positives and 10 negatives for atypical BCR–ABL1 transcript), while 11 positive
samples were detected only by ddPCR. Our results highlight ddPCR usefulness, primarily when the
BCR–ABL1/ABL1 level is less than 1.5% and NESTED PCR results are often inaccurate. Furthermore,
we identified 3 patients who maintained a deep molecular response for at least one year, who could
be considered good candidates for treatment-free remission approaches. Here, we describe a new
promising molecular approach, highly sensitive, to monitor atypical BCR–ABL1 patients, paving the
foundation to include them in treatment-free remission protocols.
Keywords: chronic myeloid leukemia; BCR–ABL1; atypical transcripts; MRD monitoring;
treatment-free remission; digital PCR
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1. Introduction
Chronic myeloid leukemia (CML) is characterized by a BCR–ABL1 fusion protein, originating
from the translocation between chromosome 9 and 22 (t(9;22)), which is also the molecular marker for
the evaluation of the minimal residual disease (MRD) in CML [1]. The majority of CML patients carry a
“canonical” t(9;22) translocation characterized by chromosomal breakpoints located on exon 13 or 14 of
the BCR gene and on exon 2 of the ABL1 gene (respectively, the e13a2 and e14a2 fusion transcripts) [2].
However, in a small proportion of CML patients (1–2%), breakpoints on chromosomes 9 and 22 are
located in unusual regions, giving rise to atypical rare transcripts, such as e13a3, e14a3, and e19a2.
Quantitative real-time PCR (RT–PCR) is the standardized method for molecular response evaluation,
but no assays have been set to quantify these rare transcripts [3]. Currently, MRD monitoring for
patients that carry atypical transcripts is performed almost exclusively by non-quantitative methods,
such as qualitative NESTED PCR [3]. The use of qualitative methods hinders the identification of the
achievement of a major molecular response (MMR), which represents a fundamental prognostic factor
for predicting progression and deciding therapy. In an era in which the response to tyrosine kinase
inhibitors (TKI) is defined in terms of MMR or deep molecular response (DMR), it is difficult to establish
the degree of response of patients with atypical transcripts in the absence of quantitative methodologies.
Furthermore, in the last few years, several clinical discontinuation trials have demonstrated that
40–60% of chronic phase CML patients, who have achieved a stable DMR, can stop TKI without
relapsing, reducing the treatment side effects, increasing CML patients’ life quality, and altogether
decreasing the cost of therapy [4]. Currently, patients showing atypical transcripts are routinely
excluded from the possibility of a treatment-discontinuation approach for safety reasons because of
the inability to quantify their molecular response [5]. Recently, seven patients with atypical transcripts
who have successfully discontinued their treatment due to severe toxicities were observed in clinical
practice [6], also suggesting the feasibility of a treatment-free remission approach in these subjects.
These observations highlight the need to develop new technologies for monitoring the disease status
in atypical cases.
Droplet digital PCR (ddPCR) has recently emerged as a possible alternative or complement
to RT-PCR to monitor low levels of disease [7,8]. ddPCR is based on water–oil emulsion droplet
technology and, implementing PCR data with Poisson statistics, allows us to quantify the number
of target molecules in a sample. Furthermore, ddPCR allows the absolute quantification of target
molecules without the use of standard curves, and this characteristic seems appealing for the monitoring
of molecular response. In comparison to RT–PCR, ddPCR has a higher reproducibility and may require
a shorter standardization process [9].
In the present study, we developed a method for the evaluation of molecular response in CML
patients characterized by atypical breakpoints based on ddPCR in order to improve the prognostic
information that could allow TKI discontinuation and/or guide the therapeutic choice.
2. Experimental Section
2.1. Cohort of Patients
After obtaining informed consent, peripheral blood (PB) and bone marrow (BM) were collected
at diagnosis and during follow-up from 11 CML patients: 3 patients with e13a3, 2 with e14a3, and 6
with e19a2. A total of 65 RNA samples (13 BM and 52 PB) were collected from three Italian diagnostic
laboratories. The mean time from diagnosis was 26 months, ranging from 1 to 104 months of follow-up.
Total RNA was reverse transcribed to complementary DNA using M-MLV reverse transcriptase,
RNAse inhibitor, and random hexamer primers (respectively, #28025013, #N8080119, and #N8080127,
Thermo Fisher Scientific, Waltham, MA, USA), following the manufacturer’s recommendations.
The study was approved by the ethics committee of San Luigi Gonzaga Hospital (approval
number: 212/2015).
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2.2. Standard Molecular Analysis
To assess the type of transcripts, BCR–ABL1 was sequenced by the Sanger method, using the
primers described in van Dongen et al. [10].
Monitoring of the patients’ follow-up was routinely performed in each laboratory with NESTED
PCR, as described by van Dongen et al. [10].
2.3. ddPCR Molecular Analysis
Different primers and MGB-probes were designed, flanking the BCR–ABL1 breakpoints (e13a3,
a14a3, and e19a2), by using Primer Express 3.0 (Thermo Fisher Scientific, Waltham, MA, USA).
Primer efficiency was calculated for each transcript with RT–PCR (CFX96, BioRad, Hercules, CA, USA)
by using serial dilutions of cDNA from positive patients at diagnosis. The specificity of each amplicon
was evaluated by analyzing the melting curve. Furthermore, we checked that selected primers and
probes, listed in Table 1, do not amplify canonical BCR–ABL1 transcripts (e13a2 and e14a2). The ABL1
(#Hs01104728_m1, Thermo Fisher Scientific, Waltham, MA, USA) gene was used as an internal control.
Table 1. Primers and probes used for droplet digital PCR (ddPCR) assays.
Primers/Probes Sequences 5′-3′ Final PCR Concentrations (nM)
e13 forward TCGTGTGTGAAACTCCAGACTGT 900
e14 forward CCACTGGATTTAAGCAGAGTTCAA 900
a3 reverse CTTCACACCATTCCCCATTG 900
a3 probe (FAM™-MGB) TGAAAAGCTCCGGGTCT 250
e19 forward CACTGAAGGCAGCCTTCGA 900
a2 reverse GAGGCTCAAAGTCAGATGCTACTG 900
a2 probe (FAM™-MGB) TCAAAGCCCTTCAGCG 250
The BCR–ABL1 fusion and ABL1 transcripts were tested in a multiplex, where probes for
BCR–ABL1 detection were labeled with FAMTM, while the probe for ABL1 detection was labeled with
VIC®fluorochrome in the same well. Each replicate was partitioned into ~20,000 droplets by a droplet
generator (QX200™Droplet Generator, BioRad, Hercules, CA, USA) and each droplet was amplified by
using ddPCR™ Supermix for Probes (No dUTP; BioRad, Hercules, CA, USA) and the thermal cycling
conditions suggested by the manufacturer. Final concentrations of custom primers and probes are listed
in Table 1, while the ABL1 assay was diluted following the manufacturer’s indications. Each sample
was then loaded onto the QX200™ Droplet Reader (BioRad, Hercules, CA, USA), and ddPCR data
were analyzed with QuantaSoft™ analysis software (version 1.7.4, BioRad, Hercules, CA, USA).
Each sample was analyzed in triplicate, and 100 ng of initial RNA were loaded for each well.
The target concentration in each sample was expressed as a percentage of BCR–ABL1/ABL1. The limit
of detection (LoD) of each assay was calculated mixing the RNA of samples without BCR–ABL1
translocation with an increasing amount of RNA from patients with atypical transcripts (0%, 0.001%,
0.01%, 0.1%, 1%, and 10%).
3. Results
3.1. ddPCR Assays Assessment
Among the designed primers, we selected the best sets based on the evaluation of the efficiency.
Selected primers showed high linearity (coefficient of correlation R2 = 0.9988, 0.9879 and 0.9984 for
e13a3, e14a3 and e19a2, respectively) and efficiency (E = 102.6%, 95%, and 95.9% for e13a3, e14a3,
and e19a2, respectively; Figure 1a). Successively, to estimate the LoD of the ddPCR assays, we simulated
different MRD patients’ conditions. In detail, we mixed at different concentration (10%, 1%, 0.1%, 0.01%,
0.001%, and 0%) RNA from positive patients with a pool of RNA without BCR–ABL1 fusion transcript.
The results indicated that our assays could quantify a reduction of the BCR–ABL1 transcript of up
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to 10-4. No positive droplets were detected in the sample used as a negative control (0% BCR–ABL1
transcript). Furthermore, the curves obtained showed very high linearity (coefficient of correlation R2
= 0.999 for all the assays; Figure 1b). Our data indicated that ddPCR assays also allow the detection of
low levels of BCR–ABL1 transcript (0.001%), with high specificity.
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Figure 1. (a) Primers efficiency calculated by using RT–PCR. The ten-fold serial dilutions are linear
over four/five logs. Data represent two replicates of each dilution. (E: efficiency; R2: coefficient of
correlation). (b) Limit of detection (LoD) estimation of ddPCR assays assessed by mixing at different
percentage positive patient’s RNA with a pool of RNA without BCR–ABL1 fusion transcript (10%, 1%,
0.1%, 0.01%, 0.001%, and 0%). LoD for each assay is highlighted in blue boxes.
3.2. BCR–ABL1 Evaluation in Patients
The BCR–ABL1 fusion transcript was evaluated in patients’ samples, at diagnosis, and during
follow-up by NESTED PCR, performed routinely by each laboratory, and by ddPCR. ddPCR generated
valuable data for all the samples analyzed; by contrast, NESTED PCR failed to evaluate 4 of these,
probably due to the quality of RNA. ddPCR and NESTED PCR identified congruently 10 negative and
40 positive samples, while 11 were identified as positive only in ddPCR. To note, all these incongruently
samples showed a low percentage of BCR–ABL1/ABL1, ranging between 0.008% and 1.31%. All the
non-concordant samples were re-evaluated a second time with both the assays and all the results of the
first analysis were confirmed. The agreement between ddPCR and NESTED PCR was evaluated by
McNemar’s test that highlighted a marked difference in the proportion of disagreement data (p <0.01;
Figure 2a). Moreover, the discriminatory ability of NESTED PCR was random in the ranges between
0.008% and 1.31% of the BCR–ABL1/ABL1 transcript, suggesting reduced robustness of the NESTED
PCR method near 1% of atypical transcripts (Figure 2b).
Results of the ddPCR analysis forBCR–ABL1 quantification of patients with e13a3, e14a3, and e19a2
are shown in Figure 3. Seven points of follow-up have both BM and PB samples, and we found that
results were concordant, confirming the data published in the literature [11,12]. For these cases, we only
reported the PB results in the graphs for an easier interpretation. A summary of all the molecular
analysis is reported in Supplementary Table S1.
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Figure 2. (a) Agreement chart for comparing BCR–ABL1 level evaluation techniques. In agreement
plots, the black blocks indicate the accordance of results between ddPCR and NESTED PCR. The 2 × 2
table alongside underlines the differences between ddPCR and NESTED PCR, reporting the nu ber of
samples positiv s (BCR–ABL1/ABL1 >0%) and negativ s (BCR–ABL1/ABL1 equal to 0%) obtained with
both the methods. (b) T e graphs indicate all the percentages of BCR–ABL1/ABL1 identified n CML
patients with ddPCR and sorted from 0% to 83%. Zoom of the regi n und r 1.32% of BCR–ABL1/ABL1
is shown in the light blue box. Grey dots: congruent results; red dots: discordant results (samples
positive in ddPCR, but negative in NESTED PCR).
Among the e13a3 group, Patient 1 showed a decreased expression of BCR–ABL1 with a percentage
of transcript less than 0.1% that was no longer detectable 36 months after TKI therapy; Patient 2
acquired the T315I mutation after 8 months of TKI therapy, while Patient 3 had a constant reduction in
BCR–ABL1 levels, undetectable from months 59 to 72 (negative for more than 1 year) of TKI treatment
(Figure 3a).
In the 14a3 group, Patient 4 s owed an optimal response to TKI treat ent, with a percentage of
BCR–ABL1 of 0.01% only at month 36 after therapy and was no more detectable from months 48 to 71
(negativ for about 2 years). Patient 5 showed BCR–ABL1 levels from 0.08% to 0.52% during all the
time of TKI administration (104 months; Figure 3b).
Among the e19a2 group, only Patient 7 achieved a BCR–ABL1/ABL1 level under 0.01% after
36 months and became negative after 46 months of TKI treatment (DMR for about 1 year); Patient 8
acquired T315I mutation; all the other patients showed a reduction in BCR–ABL1 levels that remained
detectable by ddPCR during the entire follow-up, while NESTED PCR failed to detect several of these
cases (Figure 3c).
The data indicated that our ddPCR assays were mor effective than NESTED PCR in defining
the molecular r sponse in these patie s, managing to identify three patients who have achieved and
maintained a DMR for at least one year.
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4. Discussion
The introduction of TKI has completely changed CML management, helping to improve the
response rate, survival, and quality of life of patients [13]. BCR–ABL1 levels represent the molecular
marker for the evaluation of MRD, defining the depth of molecular remission, and guiding clinical
decisions [14]. Differently from the majority of CML patients, 1–2% of these show breakpoints on
chromosomes 9 and 22 located in unusual regions, giving rise to atypical transcripts.
We describe a new method based on ddPCR for the absolute quantification of BCR–ABL1 levels in
CML patients with atypical transcripts. Despite the fact that NESTED PCR and Sanger sequencing
remain useful to diagnose and identify the BCR–ABL1 transcripts, we demonstrate that our ddPCR
assays are effective in defining the molecular response in these patients, improving clinical information
and guiding therapeutic decisions. Our assay shows good efficiency and a very low LoD, allowing
us to also identify positive samples when the BCR–ABL1 level was so low that NESTED PCR was
inaccurate. In particular, NESTED PCR was imprecise when the transcript level was lower than 1%,
and the positivity could only be detected with a second PCR step, suggesting that it is a not suitable
technique for a precise MRD assessment. By contrast, ddPCR results can be considered more reliable
because positive samples showed a percentage of BCR–ABL1/ABL1 greater than LoD identified in the
setting analysis.
Recent studies have shown that discontinuing TKI treatment in patients who have achieved
a stable DMR could decrease the cost of therapy and altogether reduce the treatment side effects,
increasing the quality of life of CML patients [4].
Despite the fact that current guidelines do not recommend discontinuation for patients with
atypical transcripts, our group has previously described 7 cases that have successfully discontinued
the treatment due to severe comorbidities [6], also suggesting the need for quantitative methodologies
for the atypical transcripts. Of note, we identified at least 3 patients (subject 3 e13a3, 4 e14a3 and 7
e19a2) who achieved and maintained a DMR for at least one year. These patients could represent good
candidates for MRD monitoring in view of a possible suspension of TKI treatment.
In conclusion, we have described a new highly sensitive and specific method for molecular
monitoring of atypical BCR–ABL1 fusion transcripts in CML patients that helps in the definition of
MRD levels to better delineate a therapeutic strategy and the optimal time for discontinuation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/5/1457/s1.
Table S1: Summary of all molecular analyses.
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